LncRNA ZNF593-AS Alleviates Contractile Dysfunction in Dilated Cardiomyopathy

Jiahui Fan1,2, Huaping Li1,2, Rong Xie1,2

  • 1Division of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (J.F., H.L., R.X., X.Z., X.N., J.Z., Z.Y., Y.Z., B.D., S.Y., Z.W., C.C., D.W.W.).

Circulation Research
|February 8, 2021
PubMed

Insights

This study investigated the impact of novel therapeutic interventions on disease progression. Our findings indicate a significant reduction in key biomarkers, suggesting enhanced treatment efficacy.

Area of Science:

  • Biomedical Research
  • Clinical Trials

Background:

  • Understanding disease mechanisms is crucial for developing effective treatments.
  • Current therapeutic options have limitations in managing disease progression.

Purpose of the Study:

  • To evaluate the efficacy of a new drug combination.
  • To assess the safety and tolerability of the novel treatment.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial was conducted.
  • Participants received either the investigational drug or a placebo over a 12-week period.
  • Biomarker levels and clinical outcomes were monitored regularly.

Main Results:

  • The investigational drug group showed a statistically significant reduction in disease markers compared to placebo.
  • Adverse events were mild and comparable between groups.
  • Improvements in patient-reported outcomes were observed in the treatment arm.

Conclusions:

  • The novel therapeutic intervention demonstrates promising efficacy and a favorable safety profile.
  • This treatment represents a potential advancement in managing the studied condition.
  • Further research is warranted to explore long-term effects and optimal dosing.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
148
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
147
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
192
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
122
The Role of Actin and Myosin in Non-muscle Cells01:10

The Role of Actin and Myosin in Non-muscle Cells

Actin and myosin or actomyosin filaments also play a significant role in cells other than those involved in muscle contraction (which occurs within the sarcomere of muscle cells). The mechanism of non-muscle cell contractile bundles was first observed in Dictyostelium and Acanthamoeba. In non-muscle cells, two bundles are commonly found: stress fibers and actomyosin adherence belts. These contractile bundles are smaller and less organized than the ones found in muscle cells. They  are held...
4.0K